IP Library › Granted Patent US 8,147,833
Granted Patent B2
US 8,147,833 · App. 12/528,439 · Granted Apr 3, 2012

Prevention and treatment of synucleinopathic and amyloidogenic disease

Assignees: Neotope Biosciences Limited; The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,147,833
App. No.
12/528,439
Granted
Apr 3, 2012
Kind
B2
Abstract

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Claims (4)

1. A method of treating, reducing the risk of, lessening the severity of, or delaying the outset of a disease characterized by Lewy bodies or alpha-synuclein aggregation in the brain, the method comprising administering to a patient having or at risk of the disease an effective regime of an antibody that specifically binds to human alpha-synuclein (SEQ ID:1), wherein the antibody is 1H7 (ATCC accession number PTA-8220) or a humanized or chimeric form thereof.

2. The method of claim 1 , wherein the antibody is an antibody of human IgG1 isotype.

3. The method of claim 1 , wherein the antibody has the CDRs of antibody 1H7 as defined by Kabat.

4. The method of claim 1 , wherein the antibody has the CDRs of antibody 1H7 as defined by Chothia.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2016
From: NEOTOPE BIOSCIENCES LIMITED
To: PROTHENA BIOSCIENCES LIMITED
Reel/Frame 037633/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2012
From: ELAN PHARMACEUTICALS, INC.
To: CRIMAGUA LIMITED
Reel/Frame 027519/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2012
From: CRIMAGUA LIMITED
To: JANSSEN ALZHEIMER IMMUNOTHERAPY
Reel/Frame 027519/0144 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2012
From: JANSSEN ALZHEIMER IMMUNOTHERAPY
To: NEOTOPE BIOSCIENCES LIMITED
Reel/Frame 027519/0166 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEES AND ATTACHED DOCUMENT PREVIOUSLY RECORDED ON REEL 023186 FRAME 0375. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. Recorded Dec 4, 2009
From: SCHENK, DALE B.; BUTTINI, MANUEL J.; CHILCOTE, TAMIE J.; GAMES, KATE DORA; MASLIAH, ELIEZER; ROCKENSTEIN, EDWARD
To: ELAN PHARMACEUTICALS, INC.; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 023606/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2009
From: SCHENK, DALE B.; MASLIAH, ELIEZER
To: ELAN PHARMACEUTICALS, INC; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 023186/0375 →
Continuity (4)
Continuation In Part 11697646 · Apr 6, 2007
Continuation In Part 11710248 · Feb 23, 2007
Provisional Application 60984721 · Nov 1, 2007
Related Publication 20100086545A1 · Apr 8, 2010